Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.

Torralva PR, Janowsky A.

J Pharmacol Exp Ther. 2019 Sep 6. pii: jpet.119.258566. doi: 10.1124/jpet.119.258566. [Epub ahead of print]

2.

Activation of Trace Amine-Associated Receptor 1 Stimulates an Antiapoptotic Signal Cascade via Extracellular Signal-Regulated Kinase 1/2.

Shi X, Swanson TL, Miner NB, Eshleman AJ, Janowsky A.

Mol Pharmacol. 2019 Oct;96(4):493-504. doi: 10.1124/mol.119.116798. Epub 2019 Aug 13.

PMID:
31409621
3.

The Role of Biogenic Amine Transporters in Trace Amine-Associated Receptor 1 Regulation of Methamphetamine-Induced Neurotoxicity.

Miner NB, Phillips TJ, Janowsky A.

J Pharmacol Exp Ther. 2019 Oct;371(1):36-44. doi: 10.1124/jpet.119.258970. Epub 2019 Jul 18.

PMID:
31320495
4.

Taar1 gene variants have a causal role in methamphetamine intake and response and interact with Oprm1.

Stafford AM, Reed C, Baba H, Walter NA, Mootz JR, Williams RW, Neve KA, Fedorov LM, Janowsky AJ, Phillips TJ.

Elife. 2019 Jul 9;8. pii: e46472. doi: 10.7554/eLife.46472.

5.

Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists.

Tosh DK, Ciancetta A, Mannes P, Warnick E, Janowsky A, Eshleman AJ, Gizewski E, Brust TF, Bohn LM, Auchampach JA, Gao ZG, Jacobson KA.

ACS Omega. 2018 Oct 31;3(10):12658-12678. doi: 10.1021/acsomega.8b01237. Epub 2018 Oct 4.

6.

Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters.

Eshleman AJ, Nagarajan S, Wolfrum KM, Reed JF, Swanson TL, Nilsen A, Janowsky A.

Psychopharmacology (Berl). 2019 Mar;236(3):939-952. doi: 10.1007/s00213-018-5059-5. Epub 2018 Nov 5.

PMID:
30397775
7.

Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors.

Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A.

Biochem Pharmacol. 2018 Dec;158:27-34. doi: 10.1016/j.bcp.2018.09.024. Epub 2018 Sep 25.

PMID:
30261175
8.

Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.

Provencher BA, Eshleman AJ, Johnson RA, Shi X, Kryatova O, Nelson J, Tian J, Gonzalez M, Meltzer PC, Janowsky A.

J Med Chem. 2018 Oct 25;61(20):9121-9131. doi: 10.1021/acs.jmedchem.8b00542. Epub 2018 Oct 4.

PMID:
30240563
9.

Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor.

Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A.

J Pharmacol Exp Ther. 2018 Aug;366(2):367-376. doi: 10.1124/jpet.118.248120. Epub 2018 Jun 11.

PMID:
29891587
10.

Verification of a genetic locus for methamphetamine intake and the impact of morphine.

Eastwood EC, Eshleman AJ, Janowsky A, Phillips TJ.

Mamm Genome. 2018 Apr;29(3-4):260-272. doi: 10.1007/s00335-017-9724-5. Epub 2017 Nov 10.

11.

Trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity.

Miner NB, Elmore JS, Baumann MH, Phillips TJ, Janowsky A.

Neurotoxicology. 2017 Dec;63:57-69. doi: 10.1016/j.neuro.2017.09.006. Epub 2017 Sep 15.

12.

Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters.

Tosh DK, Janowsky A, Eshleman AJ, Warnick E, Gao ZG, Chen Z, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA.

J Med Chem. 2017 Apr 13;60(7):3109-3123. doi: 10.1021/acs.jmedchem.7b00141. Epub 2017 Mar 20.

13.

The combined effects of 3,4-methylenedioxymethamphetamine (MDMA) and selected substituted methcathinones on measures of neurotoxicity.

Miner NB, O'Callaghan JP, Phillips TJ, Janowsky A.

Neurotoxicol Teratol. 2017 May;61:74-81. doi: 10.1016/j.ntt.2017.02.003. Epub 2017 Feb 16.

14.

Structure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release.

Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Swanson T, Johnson RA, Janowsky A.

J Pharmacol Exp Ther. 2017 Jan;360(1):33-47. Epub 2016 Oct 31.

15.

Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.

Zou MF, Keck TM, Kumar V, Donthamsetti P, Michino M, Burzynski C, Schweppe C, Bonifazi A, Free RB, Sibley DR, Janowsky A, Shi L, Javitch JA, Newman AH.

J Med Chem. 2016 Apr 14;59(7):2973-88. doi: 10.1021/acs.jmedchem.5b01612. Epub 2016 Apr 1.

16.

Genetic Polymorphisms Affect Mouse and Human Trace Amine-Associated Receptor 1 Function.

Shi X, Walter NA, Harkness JH, Neve KA, Williams RW, Lu L, Belknap JK, Eshleman AJ, Phillips TJ, Janowsky A.

PLoS One. 2016 Mar 31;11(3):e0152581. doi: 10.1371/journal.pone.0152581. eCollection 2016.

17.

Rigid Adenine Nucleoside Derivatives as Novel Modulators of the Human Sodium Symporters for Dopamine and Norepinephrine.

Janowsky A, Tosh DK, Eshleman AJ, Jacobson KA.

J Pharmacol Exp Ther. 2016 Apr;357(1):24-35. doi: 10.1124/jpet.115.229666. Epub 2016 Jan 26.

18.

Commonalities and Distinctions Among Mechanisms of Addiction to Alcohol and Other Drugs.

Ozburn AR, Janowsky AJ, Crabbe JC.

Alcohol Clin Exp Res. 2015 Oct;39(10):1863-77. doi: 10.1111/acer.12810. Review.

19.

Trace Amine-Associated Receptor 1 Regulation of Methamphetamine Intake and Related Traits.

Harkness JH, Shi X, Janowsky A, Phillips TJ.

Neuropsychopharmacology. 2015 Aug;40(9):2175-84. doi: 10.1038/npp.2015.61. Epub 2015 Mar 5.

20.

Neuroimmune basis of methamphetamine toxicity.

Loftis JM, Janowsky A.

Int Rev Neurobiol. 2014;118:165-97. doi: 10.1016/B978-0-12-801284-0.00007-5. Review.

21.

Ractopamine, a livestock feed additive, is a full agonist at trace amine-associated receptor 1.

Liu X, Grandy DK, Janowsky A.

J Pharmacol Exp Ther. 2014 Jul;350(1):124-9. doi: 10.1124/jpet.114.213116. Epub 2014 May 5.

22.

Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro.

Janowsky A, Eshleman AJ, Johnson RA, Wolfrum KM, Hinrichs DJ, Yang J, Zabriskie TM, Smilkstein MJ, Riscoe MK.

Psychopharmacology (Berl). 2014 Jul;231(14):2771-83. doi: 10.1007/s00213-014-3446-0. Epub 2014 Feb 2.

23.

Effect of Iboga alkaloids on ยต-opioid receptor-coupled G protein activation.

Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, Bornmann WG, Eshleman AJ, Janowsky A, Simon ER, Reith ME, Alper K.

PLoS One. 2013 Oct 16;8(10):e77262. doi: 10.1371/journal.pone.0077262. eCollection 2013.

24.

Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.

Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB.

Psychopharmacology (Berl). 2014 Mar;231(5):875-88. doi: 10.1007/s00213-013-3303-6. Epub 2013 Oct 19.

25.

Substituted methcathinones differ in transporter and receptor interactions.

Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A.

Biochem Pharmacol. 2013 Jun 15;85(12):1803-15. doi: 10.1016/j.bcp.2013.04.004. Epub 2013 Apr 10.

26.

Formylated polyamines as peptidomimetics.

Javor S, Janowsky A, Johnson R, Wolfrum K, Tadayoni-Rebek M, Rebek J Jr.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6580-2. doi: 10.1016/j.bmcl.2012.09.008. Epub 2012 Sep 13.

PMID:
23017884
27.

Melittin initiates dopamine transporter internalization and recycling in transfected HEK-293 cells.

Keith DJ, Wolfrum K, Eshleman AJ, Janowsky A.

Eur J Pharmacol. 2012 Sep 5;690(1-3):13-21. doi: 10.1016/j.ejphar.2012.05.020. Epub 2012 Jun 5.

28.

Substituted heteroaromatic compounds: effect on nicotine self-administration in rats.

Cashman JR, Okolotowicz K, Cerny M, Johnson R, Janowsky A, Azar MR.

Psychopharmacology (Berl). 2012 Jun;221(4):637-48. doi: 10.1007/s00213-011-2608-6. Epub 2012 Jan 5.

PMID:
22218454
29.

Abuse liability profile of three substituted tryptamines.

Gatch MB, Forster MJ, Janowsky A, Eshleman AJ.

J Pharmacol Exp Ther. 2011 Jul;338(1):280-9. doi: 10.1124/jpet.111.179705. Epub 2011 Apr 7.

30.

The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.

Purushotham M, Sheri A, Pham-Huu DP, Madras BK, Janowsky A, Meltzer PC.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):48-51. doi: 10.1016/j.bmcl.2010.11.076. Epub 2010 Nov 21.

31.

Melittin stimulates fatty acid release through non-phospholipase-mediated mechanisms and interacts with the dopamine transporter and other membrane-spanning proteins.

Keith DJ, Eshleman AJ, Janowsky A.

Eur J Pharmacol. 2011 Jan 15;650(2-3):501-10. doi: 10.1016/j.ejphar.2010.10.023. Epub 2010 Oct 20.

32.

Genetically correlated effects of selective breeding for high and low methamphetamine consumption.

Wheeler JM, Reed C, Burkhart-Kasch S, Li N, Cunningham CL, Janowsky A, Franken FH, Wiren KM, Hashimoto JG, Scibelli AC, Phillips TJ.

Genes Brain Behav. 2009 Nov;8(8):758-71. doi: 10.1111/j.1601-183X.2009.00522.x. Epub 2009 Jul 21.

33.

Discovery of dual function acridones as a new antimalarial chemotype.

Kelly JX, Smilkstein MJ, Brun R, Wittlin S, Cooper RA, Lane KD, Janowsky A, Johnson RA, Dodean RA, Winter R, Hinrichs DJ, Riscoe MK.

Nature. 2009 May 14;459(7244):270-3. doi: 10.1038/nature07937. Epub 2009 Apr 8.

PMID:
19357645
34.

2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.

Voelker T, Xia H, Fandrick K, Johnson R, Janowsky A, Cashman JR.

Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. doi: 10.1016/j.bmc.2009.01.023. Epub 2009 Jan 15.

PMID:
19201198
35.

Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.

Cashman JR, Voelker T, Johnson R, Janowsky A.

Bioorg Med Chem. 2009 Jan 1;17(1):337-43. doi: 10.1016/j.bmc.2008.10.065. Epub 2008 Nov 5.

PMID:
19014888
36.

Uptake and release of neurotransmitters.

Janowsky A, Neve K, Eshleman AJ.

Curr Protoc Neurosci. 2001 May;Chapter 7:Unit7.9. doi: 10.1002/0471142301.ns0709s02.

PMID:
18428535
37.

Lobeline effects on tonic and methamphetamine-induced dopamine release.

Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A.

Biochem Pharmacol. 2008 Mar 15;75(6):1411-5. doi: 10.1016/j.bcp.2007.11.019. Epub 2007 Dec 4.

38.
39.

Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.

Kelly JX, Smilkstein MJ, Cooper RA, Lane KD, Johnson RA, Janowsky A, Dodean RA, Hinrichs DJ, Winter R, Riscoe M.

Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40. Epub 2007 Sep 10.

40.

Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain.

Basile AS, Janowsky A, Golembiowska K, Kowalska M, Tam E, Benveniste M, Popik P, Nikiforuk A, Krawczyk M, Nowak G, Krieter PA, Lippa AS, Skolnick P, Koustova E.

J Pharmacol Exp Ther. 2007 Jun;321(3):1208-25. Epub 2007 Feb 26.

PMID:
17325229
41.

Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter.

Froimowitz M, Gu Y, Dakin LA, Nagafuji PM, Kelley CJ, Parrish D, Deschamps JR, Janowsky A.

J Med Chem. 2007 Jan 25;50(2):219-32.

PMID:
17228864
42.

Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.

Popik P, Krawczyk M, Golembiowska K, Nowak G, Janowsky A, Skolnick P, Lippa A, Basile AS.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):857-73. Epub 2006 Apr 25.

PMID:
16636898
43.

Hydrogen ion concentration differentiates effects of methamphetamine and dopamine on transporter-mediated efflux.

Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A.

J Neurochem. 2006 Feb;96(4):1149-59. Epub 2006 Jan 17.

44.

Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.

Wilhelm CJ, Johnson RA, Lysko PG, Eshleman AJ, Janowsky A.

J Pharmacol Exp Ther. 2004 Sep;310(3):1142-51. Epub 2004 Apr 21.

PMID:
15102929
45.

Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.

Shimazu S, Tsunekawa H, Yoneda F, Katsuki H, Akaike A, Janowsky A.

Eur J Pharmacol. 2003 Dec 15;482(1-3):9-16.

PMID:
14659999
46.

"Broad spectrum" antidepressants: is more better for the treatment of depression?

Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS.

Life Sci. 2003 Nov 7;73(25):3175-9. Review.

PMID:
14561522
47.

The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study.

Messamore E, Hoffman WF, Janowsky A.

Schizophr Res. 2003 Aug 1;62(3):251-8.

PMID:
12837522
48.

Bivalent biogenic amine reuptake inhibitors.

Fandrick K, Feng X, Janowsky A, Johnson R, Cashman JR.

Bioorg Med Chem Lett. 2003 Jul 7;13(13):2151-4.

PMID:
12798324
49.

Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding, distribution, and function in female macaques.

Lu NZ, Eshleman AJ, Janowsky A, Bethea CL.

Mol Psychiatry. 2003 Mar;8(3):353-60.

PMID:
12660809
50.

Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.

Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS.

Eur J Pharmacol. 2003 Feb 14;461(2-3):99-104.

PMID:
12586204

Supplemental Content

Loading ...
Support Center